This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

GlaxoSmithKline Sales Down In Q3 Against Good Underlying Momentum In The Business

LONDON, October 31, 2012 /PRNewswire/ --

GlaxoSmithKline released third quarter results today with Finance Director Simon Dingemans saying the pharma group was on course to deliver growth in Q4 and sales "broadly in line" with the previous year.

In a video interview Mr Dingemans said while factors such as costs from disposals and weak European sales had added to a difficult quarter where total sales were down 5%, performances from promoted and new products plus R&D developments meant shareholders saw dividends up 6% year-on-year.  

"I think we're pleased with the progress that the growth drivers and the core strategic businesses are making and I think overall that leaves us feeling that we have good momentum going into the fourth quarter."

The interview and transcript are available now on http://www.cantos.com/company/GlaxoSmithKline.

MerchantCantos produces in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email prnsupport@merchantcantos.com or phone +44-207-936-1352.

SOURCE GlaxoSmithKline

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,077.27 -2.87 -0.02%
S&P 500 2,114.42 -3.27 -0.15%
NASDAQ 5,070.4750 -21.61 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs